Differential contribution of immune effector mechanisms to cortical demyelination in multiple sclerosis

Cortical demyelination is a widely recognized hallmark of multiple sclerosis (MS) and correlate of disease progression and cognitive decline. The pathomechanisms initiating and driving gray matter damage are only incompletely understood. Here, we determined the infiltrating leukocyte subpopulations...

Full description

Saved in:
Bibliographic Details
Published inActa neuropathologica Vol. 134; no. 1; pp. 15 - 34
Main Authors Lagumersindez-Denis, Nielsen, Wrzos, Claudia, Mack, Matthias, Winkler, Anne, van der Meer, Franziska, Reinert, Marie C., Hollasch, Heiko, Flach, Anne, Brühl, Hilke, Cullen, Eilish, Schlumbohm, Christina, Fuchs, Eberhard, Linington, Christopher, Barrantes-Freer, Alonso, Metz, Imke, Wegner, Christiane, Liebetanz, David, Prinz, Marco, Brück, Wolfgang, Stadelmann, Christine, Nessler, Stefan
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2017
Springer
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cortical demyelination is a widely recognized hallmark of multiple sclerosis (MS) and correlate of disease progression and cognitive decline. The pathomechanisms initiating and driving gray matter damage are only incompletely understood. Here, we determined the infiltrating leukocyte subpopulations in 26 cortical demyelinated lesions of biopsied MS patients and assessed their contribution to cortical lesion formation in a newly developed mouse model. We find that conformation-specific anti-myelin antibodies contribute to cortical demyelination even in the absence of the classical complement pathway. T cells and natural killer cells are relevant for intracortical type 2 but dispensable for subpial type 3 lesions, whereas CCR2 + monocytes are required for both. Depleting CCR2 + monocytes in marmoset monkeys with experimental autoimmune encephalomyelitis using a novel humanized CCR2 targeting antibody translates into significantly less cortical demyelination and disease severity. We conclude that biologics depleting CCR2 + monocytes might be attractive candidates for preventing cortical lesion formation and ameliorating disease progression in MS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0001-6322
1432-0533
DOI:10.1007/s00401-017-1706-x